Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1999 Jul;37(7):2343-5.
doi: 10.1128/JCM.37.7.2343-2345.1999.

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole

D A Sutton  1 , S E Sanche, S G Revankar, A W Fothergill, M G Rinaldi
Affiliations
Comparative Study

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole

D A Sutton et al. J Clin Microbiol. 1999 Jul.

Abstract

Amphotericin B therapy continues to be the "gold standard" in the treatment of invasive aspergillosis in the immunocompromised host. Although Aspergillus fumigatus and Aspergillus flavus constitute the major species, several reports have described invasive pulmonary or disseminated disease due to the less common Aspergillus terreus and dismal clinical outcomes with high-dose amphotericin B. We therefore evaluated 101 clinical isolates of A. terreus for their susceptibility to amphotericin B and the investigational triazole voriconazole by using the National Committee for Clinical Laboratory Standards M27-A method modified for mould testing. Forty-eight-hour MICs indicated 98 and 0% resistance to amphotericin B and voriconazole, respectively. We conclude that A. terreus should be added to the list of etiologic agents refractory to conventional amphotericin B therapy and suggest the potential clinical utility of voriconazole in aspergillosis due to this species.

PubMed Disclaimer

References

    1. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In: Lorian V, editor. Antibiotics in laboratory medicine. 4th ed. Baltimore, Md: Williams & Wilkins; 1996. p. 103.
    1. Clancy C J, Nguyen M H. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 1998;17:573–575. - PubMed
    1. Colombo A L, McGough D A, Rinaldi M G. Programs and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1993. Amphotericin B (AMB) tolerance with Aspergillus species, abstr. 748; p. 256.
    1. Das T, Vyas P, Sharma S. Aspergillus terreus postoperative endophthalmitis. Br J Ophthalmol. 1993;77:386–387. - PMC - PubMed
    1. Denning D, De Favero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke P, Sarantis N. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. UK-109-496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80; p. 126.

Publication types

MeSH terms